2023-06-12 14:58:00 ET
Shares of Kymera Therapeutics ( NASDAQ: KYMR ) rose as much as 15% on Monday amid the release of preclinical and early-stage clinical data for three of its drug candidates for blood cancer.
Kymera shares were up 8% at $24.61 at around 2:50 p.m. after hitting a high of $26.17 earlier in the day.
Late Friday, Kymera said it presented promising preclinical data for its drug candidate KT-253 at the European Hematology Association Congress.
The company also shared new Phase 1 data on its drug programs for KT-333 and KT-413 Monday at the International Conference on Malignant Lymphoma. The company plans to present updated data on both programs on June 14, with a poster presentation on KT-333 slated for June 16.
More on Kymera:
Kymera Therapeutics appoints COO
Kymera upgraded to outperform at Raymond James on improved risk/reward
For further details see:
Kymera climbs on data updates for three drug programs